The Neisseria gonorrhoeae Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neisseria gonorrhoeae Infections. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued products.

GlobalData tracks 27 drugs in development for Neisseria gonorrhoeae Infections by 21 companies/universities/institutes. The top development phase for Neisseria gonorrhoeae Infections is preclinical with 18 drugs in that stage. The Neisseria gonorrhoeae Infections pipeline has 24 drugs in development by companies and three by universities/ institutes. Some of the companies in the Neisseria gonorrhoeae Infections pipeline products market are: TherapyX, Microbiotix and Evaxion Biotech.

The key targets in the Neisseria gonorrhoeae Infections pipeline products market include Interleukin 12 (IL12), Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10), and Interleukin 12 Receptor (IL12R).

The key mechanisms of action in the Neisseria gonorrhoeae Infections pipeline product include Cell Wall Synthesis Inhibitor with one drug in Discovery. The Neisseria gonorrhoeae Infections pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Neisseria gonorrhoeae Infections pipeline products market including Small Molecule, and Vaccine.

Neisseria gonorrhoeae Infections overview

Neisseria gonorrhoeae, the bacterium accountable for the sexually transmitted infection (STI) gonorrhea, is a notable public health issue causing substantial global morbidity in both resource-rich and resource-poor nations. The diagnosis and treatment of this infection entail considerable financial expenditures each year. Similar to other sexually transmitted infections (STIs), gonorrhea has a disproportionate impact on young adults. The obligate human pathogen N. gonorrhoeae predominantly presents as urethritis in men and cervicitis in women.

For a complete picture of Neisseria gonorrhoeae Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.